Nuvation Bio (NUVB) Accumulated Expenses (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Accumulated Expenses of $32.9 million for Q1 2026, up 37.55% year-over-year from $23.9 million in Q1 2025, and down 27.26% quarter-over-quarter from $45.2 million in Q4 2025.
Nuvation Bio (NUVB) Accumulated Expenses (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Accumulated Expenses for 7 consecutive years, with $32.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 37.55% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $32.9 million (up 37.55% YoY), while the FY2025 annual figure was $45.2 million, up 37.61% from the prior year.
- Accumulated Expenses eased to $32.9 million in Q1 2026 per NUVB's latest filing, from $45.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $45.2 million in Q4 2025 and bottomed at $7.1 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $18.8 million across 5 years, with a median of $11.9 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses decreased 19.12% — and 2024, when it jumped 235.27%.
- Nuvation Bio's Accumulated Expenses stood at $9.8 million in 2022, then fell by 0.23% to $9.8 million in 2023, then surged by 235.27% to $32.8 million in 2024, then surged by 37.61% to $45.2 million in 2025, then decreased by 27.26% to $32.9 million in 2026.
- Business Quant data shows NUVB's Accumulated Expenses at $32.9 million in Q1 2026, $45.2 million in Q4 2025, and $32.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.20 Mn |
| Mar 31, 2026 | 32.86 Mn |
| Dec 31, 2025 | 45.18 Mn |
| Sep 30, 2025 | 32.58 Mn |
| Jun 30, 2025 | 24.00 Mn |
| Mar 31, 2025 | 23.89 Mn |
| Dec 31, 2024 | 32.83 Mn |
| Sep 30, 2024 | 23.51 Mn |
| Jun 30, 2024 | 19.97 Mn |
| Mar 31, 2024 | 11.30 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Sep 30, 2023 | 11.86 Mn |
| Jun 30, 2023 | 9.55 Mn |
| Mar 31, 2023 | 8.36 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Sep 30, 2022 | 9.92 Mn |
| Jun 30, 2022 | 7.61 Mn |
| Mar 31, 2022 | 7.12 Mn |
| Dec 31, 2021 | 12.14 Mn |
| Sep 30, 2021 | 8.15 Mn |